Parents' perceived safety, usability, and acceptability of vaccination through microarray patches: A preliminary multi-national cross-sectional survey
- PMID: 41805238
- PMCID: PMC12977274
- DOI: 10.1080/21645515.2026.2642457
Parents' perceived safety, usability, and acceptability of vaccination through microarray patches: A preliminary multi-national cross-sectional survey
Abstract
Microarray patches (MAPs) are an emerging, needle-free vaccination technology with potential to improve vaccine uptake and acceptability. A cross-sectional online survey was conducted to assess parents' perceptions of MAP safety, usability, and acceptability for themselves and their children. Participants were parents of children aged ≤18 y residing in Australia, Canada, the United Kingdom, or New Zealand. Responses were recorded on a 7-point Likert scale. Descriptive statistics and paired t-tests were used for analysis. A total of 102 parents participated (mean age = 40.7 y, SD = 10.6), predominantly from Canada (59.8%) and Australia (35.3%). Parents rated MAP vaccination as safe and effective (mean = 5.13; 95% CI: 4.83-5.43), easy to use (mean = 5.51; 95% CI: 5.26-5.77), and acceptable (mean = 5.43; 95% CI: 5.18-5.68). Respondents preferred MAPs over traditional needle and syringe (N&S) methods for themselves and their children, particularly citing benefits for those with needle-related anxiety. Parents expressed stronger preferences for healthcare provider administration for children compared to themselves. MAP self-administration was also viewed positively. Participants indicated greater willingness to pay more for their child to receive the MAP vaccination compared to themselves. Findings suggest that parents perceive MAPs as a safe, usable, and acceptable alternative to N&S vaccination for themselves and their children.
Keywords: Parents; acceptability; immunization; microarray patch; usability; vaccination.
Conflict of interest statement
MNB was awarded an NSW Health PhD Partnership Scholarship to examine the usability and acceptability of high-density microarray patches (HD-MAPs) under development by Vaxxas Pty Ltd. CD and SRS are investigators involved in research on the usability and acceptability of the Vaxxas HD-MAP. EM, RZS, and SB report no conflicts of interest.
References
-
- Berger MN, Mowbray ES, Farag MWA, Mathieu E, Davies C, Thomas C, Booy R, Forster AH, Skinner SR.. Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis. BMJ Glob Health [Internet]. 2023;8(10):e012247. doi: 10.1136/bmjgh-2023-012247. - DOI - PMC - PubMed
-
- Adigweme I, Yisa M, Ooko M, Akpalu E, Bruce A, Donkor S, Jarju LB, Danso B, Mendy A, Jeffries D, et al. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial. Lancet [Internet]. 2024;403(10439):1879–6. doi: 10.1016/S0140-6736(24)00532-4. - DOI - PMC - PubMed
-
- Davies C, Taba M, Deng L, Karatas C, Bag S, Ross C, Forster A, Booy R, Skinner SR. Usability, acceptability, and feasibility of a high-density microarray patch (HD-MAP) applicator as a delivery method for vaccination in clinical settings. Hum Vaccin Immunother. 2022;18(4):2018863. doi: 10.1080/21645515.2021.2018863. - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous